Charles River to acquire Frontage's bioanalysis and DMPK operations for $470M cash
Charles River Laboratories International (CRL) has agreed to acquire Frontage Holdings’ bioanalysis and drug metabolism and pharmacokinetics (DMPK) operations in Exton, Pennsylvania, for approximately $470M in cash, with an additional $75M in potential performance-based payments.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.